信立泰(002294.SZ)：SAL0137药品临床试验申请获得受理

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial application of its innovative small molecule drug SAL0137, which is intended for the treatment of elevated lipoprotein (a) levels [1] Group 1 - The drug SAL0137 is a self-developed oral small molecule medication with independent intellectual property rights [1] - The application submitted by the company is specifically for clinical trials of SAL0137 targeting elevated lipoprotein (a) [1]